🟢 Connect Biopharma is trading 9.6% up in pre-market with no confirmed company-specific catalyst

Connect Biopharma is trading 9.6% up at $2.50 after no confirmed company-specific catalyst was identified for August 21, 2026.

• Its latest material update was the August 12 quarterly report, which reported completed enrollment in two Phase 2 studies and expected September topline results.
• Broader markets are modestly higher, but the move’s specific cause remains unclear; confidence is low.